UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Ultragenyx Pharmaceutical Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
90400D108
(CUSIP Number)
December 29, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP: 90400D108 Page 1 of 5
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Capital International Investors **
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE
INSTRUCTIONS) (a)
(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
California
5 SOLE VOTING POWER
4,139,700
6 SHARED VOTING POWER
NUMBER OF
SHARES NONE
BENEFICIALL
Y OWNED BY
7 SOLE DISPOSITIVE POWER
EACH
REPORTING 4,411,165
PERSON
WITH:
8 SHARED DISPOSITIVE POWER
NONE
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,411,165 Beneficial ownership disclaimed pursuant to Rule
13d-4
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
10.3%
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IA
** A division of Capital Research and Management Company (CRMC)
CUSIP: 90400D108 Page 2 of 5
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Schedule 13G
Under the Securities Exchange Act of 1934
Amendment No.
Item 1(a) Name of Issuer:
Ultragenyx Pharmaceutical Inc.
Item 1(b) Address of Issuer's Principal Executive Offices:
60 Leveroni Court
Novato, CA 94949
Item 2(a) Name of Person(s) Filing:
Capital International Investors, division of Capital Research
and Management Company
Item 2(b) Address of Principal Business Office or, if none,
Residence:
11100 Santa Monica Boulevard
16th Floor
Los Angeles, CA 90025
Item 2(c) Citizenship: N/A
Item 2(d) Title of Class of Securities:
Common Stock
Item 2(e) CUSIP Number:
90400D108
Item 3 If this statement is filed pursuant to sections 240.13d-1(b)
or 240.13d-2(b) or (c), check whether the person filing is a:
(e) [X] An investment adviser in accordance with
section 240.13d-1(b)(1)(ii)(E).
Item 4 Ownership
Provide the following information regarding the aggregate
number and percentage of the class of securities of the issuer
identified in Item 1.
(a) Amount beneficially owned:
(b) Percent of class:
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of:
(iv) Shared power to dispose or to direct the disposition of:
See page 2
CUSIP: 90400D108 Page 3 of 5
Capital International Investors divisions of Capital Research and
Management Company ("CRMC") and Capital Bank and Trust, as well as the
following CRMC subsidiaries: Capital Guardian Trust Company, Capital
International Limited, Capital International Sarl, Capital
International K.K. and Capital International, Inc., collectively
provide investment management services under the name "Capital
International Investors." Please see Items 5 through 11 of each
reporting person's cover sheet in this Schedule 13G filing for such
person's deemed beneficial ownership of 4,411,165 shares or 10.3% of
the 42,589,056 shares believed to be outstanding.
Item 5 Ownership of Five Percent or Less of a Class. If this
statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following: [ ]
Item 6 Ownership of More than Five Percent on Behalf of Another
Person: One or more clients of Capital International Investors
have the right to receive or the power to direct the receipt of
dividends from, or the proceeds from the sale of, the Common
Stock of Ultragenyx Pharmaceutical Inc.. Capital International
Investors holds more than five percent of the outstanding
Common Stock of Ultragenyx Pharmaceutical Inc. as of December
29, 2017 on behalf of each of the following client(s):
New Perspective Fund
Item 7 Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company or Control Person: N/A
Item 8 Identification and Classification of Members of the Group:
N/A
Item 9 Notice of Dissolution of Group: N/A
Item 10 Certification
By signing below, I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and
are held in the ordinary course of business and were not
acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose
or effect.
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
Date: January 10, 2018
Signature: **Robert W. Lovelace
Name/Title: Robert W. Lovelace, Partner
Capital International Investors
CUSIP: 90400D108 Page 4 of 5
***By /s/ Walter R. Burkley
Walter R. Burkley
Attorney-in-fact
Signed pursuant to a Power of Attorney dated January 4, 2017
included as an Exhibit to Schedule 13G filed with the
Securities and Exchange Commission by Capital International
Investors on January 10, 2017 with respect to Agios
Pharmaceuticals, Inc.
CUSIP: 90400D108 Page 5 of 5